TOP > 外国特許検索 > PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES

PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES 新技術説明会

Foreign code F170009151
File No. S2015-1886-C0
Posted date 2017年8月16日
Country 世界知的所有権機関(WIPO)
International application number 2016JP071224
International publication number WO 2017018288
Date of international filing 平成28年7月20日(2016.7.20)
Date of international publication 平成29年2月2日(2017.2.2)
Priority data
  • 特願2015-150344 (2015.7.30) JP
Title PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES 新技術説明会
Abstract Provided is a new means for effectively treating diseases including autoimmune diseases and the like. This peptide fragment has an amino acid sequence from position 46 to position 73, an amino acid sequence from position 160 to position 181, or an amino acid sequence from position 235 to position 261 in the amino acid sequence of carbonic anhydrase I (CAI), and includes 35 amino acid residues or less.
Outline of related art and contending technology BACKGROUND ART
Crohn's disease and ulcerative colitis including inflammatory bowel disease (IBD) is, characterized by failure of the immune system in the intestinal tract disease. And detailed a disease not yet clear, commensal bacteria, various microbial product, a natural immunity and acquired immunity and food excessive are considered to be one of the causes of the reaction.
Immunomodulation in microenvironment is, in order to maintain local homeostasis constantly need to be finely adjusted. This adjustment can be made, site specific (for example the digestive tract environment) and, to a microbe induced by chronic exposure of the considered. Dendritic cells, plays an important role in controlling this adjustment to be responsible for the. Dendritic cells, the most potent and effective antigen presenting cell, are responsible for the induction of the initial immune response. In addition, dendritic cells are important to the formation of immune tolerance to play a role. Of immune tolerance mechanism is not fully resolved, CD4 dendritic cells+ CD25- TCD4 cells+ CD25+ Foxp3+ T controllability by to differentiate into cells, inducing an immune tolerance at the periphery T cells has been reported (see non-patent document 1) are.
Patent Document 1 is, inflammatory bowel disease in the treatment of autoimmune diseases including carbonic anhydrase I (CAI) and the pulsed tolerogenic antigen-presenting cells can be utilized have been proposed.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY
  • Inventor
  • HIASA, Yoichi
  • YAGI, Sen
  • ABE, Masanori
  • IKEDA, Yoshioh
  • YAMASHITA, Masakatsu
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
四国TLOは四国内20大学・高専のシーズをご紹介しております。シーズの詳細内容につきましては下記までお問い合わせください。
お問い合わせをお待ちしております。

PAGE TOP

close
close
close
close
close
close